The NOR-SWITCH results were presented yesterday at the United Gastro-Enterology week in Vienna, highlighting that the physician-led switching between medicines containing the originator and biosimilar versions (Remsima/Inflectra) of infliximab led to the absence of statistical difference in patient outcomes.